

Ultrasound-guided femoral access in patients with vascular closure devices: a prespecified analysis of the randomised UNIVERSAL trial

Marc-André d'Entremont^{1,2}, MD, MPH; Sulaiman Alrashidi^{3,4,5}, MD; Omar Alansari^{3,4,5}, MD; Bradley Brochu⁶, MD; Laura Heenan², MSc; Elizabeth Skuriat², MSc; Jessica Tyrwhitt², BSc; Michael Raco^{3,4,5}, MD; Michael B. Tsang^{3,4,5}, MD, MSc; Nicholas Valettas^{3,4,5}, MD, MASC; James Velianou^{3,4,5}, MD; Tej Sheth^{2,3,4,5}, MD; Matthew Sibbald^{3,4,5}, MD, PhD; Shamir R. Mehta^{2,3,4,5}, MD, MSc; Natalia Pinilla-Echeverri^{2,3,4,5}, MD, MSc; Jon-David Schwalm^{2,3,4,5}, MD, MSc; Madhu K. Natarajan^{2,3,4,5}, MD, MSc; Andrew Kelly^{3,4,5}, MD; Elie Akl⁷, MD; Sarah Tawadros⁴, MBChB; Mercedes Camargo⁴, MD, MASC; Walaa Faidi⁴, MSc; John Bauer⁴, BMRSc; Rachel Moxham⁴, BSc; James Nkurunziza^{3,4,5}, MD; Gustavo Dutra^{3,4}, MD; Jose Winter⁸, MD; Sanjit S. Jolly^{2,3,4,5*}, MD, MSc

1. Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC, Canada; 2. Population Health Research Institute, Hamilton, ON, Canada; 3. McMaster University, Hamilton, ON, Canada; 4. Hamilton Health Sciences, Hamilton, ON, Canada; 5. Niagara Health, St. Catharines, ON, Canada; 6. CK Hui Heart Centre, Royal Alexandra Hospital, Edmonton, AB, Canada; 7. McGill University Faculty of Medicine and Health Sciences, Montreal, QC, Canada; 8. Clinica Alemana De Santiago, Universidad de Desarrollo, Santiago, Chile

This paper also includes supplementary data published online at: <https://eurointervention.pronline.com/doi/10.4244/EIJ-D-22-01130>

KEYWORDS

- access site
- bleeding
- femoral

Abstract

Background: Whether ultrasound (US)-guided femoral access compared to femoral access without US guidance decreases access site complications in patients receiving a vascular closure device (VCD) is unclear.

Aims: We aimed to compare the safety of VCD in patients undergoing US-guided versus non-US-guided femoral arterial access for coronary procedures.

Methods: We performed a prespecified subgroup analysis of the UNIVERSAL trial, a multicentre randomised controlled trial of 1:1 US-guided femoral access versus non-US-guided femoral access, stratified for planned VCD use, for coronary procedures on a background of fluoroscopic landmarking. The primary endpoint was a composite of major Bleeding Academic Research Consortium 2, 3 or 5 bleeding and vascular complications at 30 days.

Results: Of 621 patients, 328 (52.8%) received a VCD (86% ANGIO-SEAL, 14% ProGlide). In patients who received a VCD, those randomised to US-guided femoral access compared to non-US-guided femoral access experienced a reduction in major bleeding or vascular complications (20/170 [11.8%] vs 37/158 [23.4%], odds ratio [OR] 0.44, 95% confidence interval [CI]: 0.23-0.82). In patients who did not receive a VCD, there was no difference between the US- and non-US-guided femoral access groups, respectively (20/141 [14.2%] vs 13/152 [8.6%], OR 1.76, 95% CI: 0.80-4.03; interaction $p=0.004$).

Conclusions: In patients receiving a VCD after coronary procedures, US-guided femoral access was associated with fewer bleeding and vascular complications compared to femoral access without US guidance. US guidance for femoral access may be particularly beneficial when VCD are used.

*Corresponding author: Population Health Research Institute, Hamilton General Hospital, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada. E-mail: sanjit.jolly@phri.ca

Abbreviations

BARC	Bleeding Academic Research Consortium
CI	confidence interval
OR	odds ratio
PCI	percutaneous coronary intervention
US	ultrasound
VCD	vascular closure device

Introduction

Transradial access reduces major vascular complications and access site bleeding compared to transfemoral access in patients undergoing coronary angiography or percutaneous coronary interventions (PCI) and is therefore recommended¹. However, femoral access is still indicated in larger bore procedures, in procedures where radial access failure has occurred, and bilateral internal mammary coronary graft angiography. Vascular and bleeding complications in femoral access can occur because of high or low punctures, multiple punctures, or inadequate haemostasis technique². Studies have demonstrated that vascular closure devices (VCD) are associated with a reduced time to haemostasis and reduced time to ambulation, with no difference in the incidence of vascular injury or mortality compared to manual compression³⁻⁵. Given the ubiquitous use of vascular closure devices for femoral access to optimise patient comfort and increase workflow, strategies to decrease vascular closure device complications are clinically important.

The UNIVERSAL trial, which randomised 621 patients, stratified by planned VCD use, to ultrasound (US) versus no US for femoral access, did not demonstrate a significant difference for the primary composite outcome of major bleeding or vascular complications⁶. In patients receiving a VCD, we hypothesised that patients with US-guided femoral access would experience fewer access site complications than patients without US-guided femoral access. The present study aims to explore the association between US-guided femoral access and VCD use on bleeding and vascular complications in the prespecified VCD subgroups of the UNIVERSAL trial.

Editorial, see page 15

Methods

STUDY DESIGN AND PATIENTS

The Routine Ultrasound Guidance for Vascular Access for Cardiac Procedures (UNIVERSAL) trial was a multicentre, open-label, investigator-driven, randomised clinical trial comparing US-guided femoral access versus no US for coronary procedures on a background of fluoroscopic landmarking for the primary composite endpoint of major bleeding and vascular complications (ClinicalTrials.gov: NCT03537118)⁶. The details of the design of the trial have been previously published⁷. Patients were eligible if referred for coronary angiogram or PCI with planned femoral access. Exclusion criteria were minimal: 1) age 18 years or younger, 2) ST-elevation myocardial infarction as the initial presentation, and 3) absence of a palpable femoral pulse. Eligible

patients were randomised 1:1, stratified by planned VCD use, to femoral access with either US or no US. The subgroup analyses were performed by actual post-randomisation VCD use in patients randomised to US versus no US as specified in the protocol. Of note, US was used only to guide the femoral puncture and not to subsequently guide the VCD deployment.

The Population Health Research Institute, a joint institute of McMaster University and Hamilton Health Sciences, conducted the UNIVERSAL trial. The trial was approved by the ethics committee at each participating centre.

CLINICAL STUDY OUTCOMES

The primary outcome was the composite of Bleeding Academic Research Consortium (BARC) 2, 3, or 5 bleeding or major vascular complications, including femoral artery pseudoaneurysm, arteriovenous fistula, retroperitoneal bleed, large haematoma more than 5 cm in diameter, or an ischaemic limb requiring intervention or surgery at 30 days.

A blinded investigator evaluated the presence of major bleeding or vascular complications at discharge. Furthermore, investigators blinded to allocation completed a comprehensive medical record review and telephone follow-up within 30 days of the index procedure.

ANGIOGRAPHIC CORE LABORATORY EVALUATION

Femoral angiograms were reviewed by blinded research personnel in the angiographic core laboratory at the Hamilton General Hospital, Hamilton, Canada. We reported the location of the femoral bifurcation, the presence of common femoral artery calcification, the successful cannulation of the common femoral artery, active bleeding, and the presence of femoral artery dissection.

STATISTICAL ANALYSIS

We presented continuous variables with normal distributions as means with standard deviations and compared groups using the Student's t-test. We presented categorical variables as absolute frequencies and percentages and compared groups using the chi-square or Fisher's exact test as appropriate. For the main outcomes, odds ratios (OR) with 95% confidence intervals (CI) were calculated. We calculated interactions between VCD subgroups and treatment allocation, using the Breslow-Day test of homogeneity, for the primary outcome, major bleeding alone, and vascular complications alone. We similarly analysed the different types of VCD. Two-tailed p-values <0.05 were considered statistically significant. We did not adjust for multiplicity. All analyses were performed using SAS version 9.4 (SAS Institute).

Results

BASELINE CHARACTERISTICS

As demonstrated in **Figure 1**, 311 patients were allocated to US compared to 310 patients who were allocated to no US on a background of fluoroscopic guidance. No patients were lost to follow-up. A total of 170 of 311 (54.7%) patients in the US arm received




Figure 1. CONSORT diagram for the UNIVERSAL trial with vascular closure device subgroups. TFA: transfemoral access; US: ultrasound; VCD: vascular closure device

a VCD, compared to 158 of 310 (51.0%) patients in the no US arm, for a total of 328 VCD patients.

The baseline characteristics were well balanced between subgroups when comparing US guidance to no US guidance, after stratification for VCD use (**Table 1**). In the VCD subgroup, the patients had a mean age of 70 years, 84 (25.6%) were female, and they had a mean body mass index of 29.4 kg/m². The VCD subgroup had a comorbid population: 178 (54.2%) had a prior myocardial infarction, 170 (51.8%) had a previous PCI, 177 (54.0%) had prior coronary artery bypass surgery, 131 (39.9%) had diabetes mellitus, 43 (13.1%) had peripheral artery disease, 49 (14.9%) had atrial fibrillation, with similar rates of comorbidities in the no VCD group. Chronic total occlusion PCI was performed in 60 (18.3%) patients in the VCD subgroup.

PROCEDURAL CHARACTERISTICS AND CORE LABORATORY DATA IN VCD PATIENTS

A 6 Fr introducer was used for most accesses (n=246/332, 74.1%), and 141 of 172 (82.0%) US-guided accesses compared to 143 of 160 (89.4%) of non-US-guided accesses received an ANGIO-SEAL (Terumo) device (**Table 2**). Closure device failures according to access site were similar in both groups, with 16/172 (9.3%) failures in the US-guided subgroup and 11/160 (6.9%) failures in the non-US-guided subgroup (p=0.42) (**Supplementary Table 1**).

Successful cannulation of the common femoral artery (above the bifurcation and below the inferior epigastric artery) occurred in 148/169 (87.6%) of the US-guided femoral access sites compared to 141/156 (90.4%) of the non-US-guided femoral access sites (p=0.42) (**Supplementary Table 2**).

MAIN OUTCOMES

In patients who received a VCD, those who were randomised to US-guided femoral access compared to non-US-guided femoral access experienced a reduction in major bleeding or vascular complications (20/170 [11.8%] vs 37/158 [23.4%], OR 0.44, 95% CI: 0.23-0.82). In patients who did not receive a VCD, there was no difference between the US-guided and non-US-guided femoral access subgroups (20/141 [14.2%] vs 13/152 [8.6%], OR 1.76, 95% CI: 0.80-4.03). We observed significant interaction (interaction p=0.004) (**Figure 2**). More specifically, patients receiving an ANGIO-SEAL who were randomised to the US group experienced significantly fewer access site complications than patients who were randomised to the no US group (OR 0.33, 95% CI: 0.15-0.71). This effect was non-significant for the ProGlide (Abbott) VCD, with the caveat of wide confidence intervals (OR 0.74, 95% CI: 0.17-3.31). There was no significant interaction (interaction p=0.29).

When considering individual outcomes in patients who received a VCD, US-randomised patients had fewer major vascular complications than no US patients (7/170 [4.1%] vs 21/158 [13.3%], OR 0.28, 95% CI: 0.10-0.71). This beneficial effect of US was not observed in patients who did not receive a VCD (13/141 [9.2%] vs 8/152 [5.3%], OR 1.82, 95% CI: 0.68-5.25; interaction p=0.004). However, in patients who received a VCD, those randomised to US guidance did not experience a decrease in major bleeding as compared to those randomised to no US guidance (16/170 [9.4%] vs 24/158 [15.2%], OR 0.58, 95% CI: 0.28-1.19). Similarly, in patients who did not receive a VCD, those randomised to US-guided femoral access did not fare better than their non-US-guided counterparts (15/141 [10.6%] vs 9/152 [5.9%] OR 1.89,

Table 1. Baseline characteristics.

Variables	Vascular closure device use (n=328)		p-value	No vascular closure device (n=293)		p-value
	US-guided (n=170)	Non-US-guided (n=158)		US-guided (n=141)	Non-US-guided (n=152)	
Demographics and comorbidities						
Age (years)	69.89±10.14	69.63±10.40	0.82	71.15±10.14	71.71±10.25	0.64
Female sex	41 (24.1%)	43 (27.2%)	0.52	39 (27.7%)	35 (23.0%)	0.36
BMI ¹ (kg/m ²)	29.91±6.01	28.79±6.35	0.10	28.99±6.08	28.90±6.60	0.90
Hypertension	144 (84.7%)	141 (89.2%)	0.22	120 (85.1%)	133 (87.5%)	0.55
Dyslipidaemia	147 (86.5%)	140 (88.6%)	0.56	126 (89.4%)	142 (93.4%)	0.21
Diabetes	74 (43.5%)	57 (36.1%)	0.17	59 (41.8%)	71 (46.7%)	0.40
Current smoker	27 (15.9%)	30 (19.0%)	0.46	13 (9.2%)	22 (14.5%)	0.17
Previous myocardial infarction	88 (51.8%)	90 (57.0%)	0.35	68 (48.2%)	73 (48.0%)	0.76
Previous PCI	87 (51.2%)	83 (52.5%)	0.81	53 (37.6%)	55 (36.2%)	0.80
Previous CABG	92 (54.1%)	85 (53.8%)	0.95	86 (61.0%)	90 (59.2%)	0.76
Previous stroke/TIA	15 (8.8%)	13 (8.2%)	0.85	10 (7.1%)	20 (13.2%)	0.09
Peripheral vascular disease	24 (14.1%)	19 (12.0%)	0.44	33 (23.4%)	34 (22.4%)	0.83
Atrial fibrillation	31 (18.2%)	18 (11.4%)	0.08	27 (19.2%)	39 (25.7%)	0.18
Chronic kidney disease	20 (11.8%)	17 (10.8%)	0.77	30 (21.3%)	26 (17.1%)	0.36
PCI performed during procedure	97 (57.1%)	92 (58.2%)	0.83	37 (26.2%)	36 (23.7%)	0.61
Indication for procedure						
Atypical chest pain	20 (11.8%)	15 (9.5%)	0.51	17 (12.1%)	31 (20.4%)	0.05
Stable angina	54 (31.8%)	33 (20.9%)	0.03	34 (24.1%)	35 (23.0%)	0.83
Silent ischaemia	3 (1.8%)	3 (1.9%)	1.0	5 (3.6%)	6 (4.0%)	1.0
Unstable angina	21 (12.4%)	11 (7.0%)	0.10	16 (11.4%)	7 (4.6%)	0.03
NSTEMI	30 (17.7%)	38 (24.1%)	0.15	24 (17.0%)	31 (20.4%)	0.46
Planned PCI	14 (8.2%)	9 (5.7%)	0.37	6 (4.3%)	3 (2.0%)	0.32
CTO PCI	27 (15.9%)	33 (20.9%)	0.24	15 (10.6%)	13 (8.6%)	0.54
Valvular assessment	2 (1.2%)	2 (1.3%)	1.0	7 (5.0%)	1 (0.7%)	0.61
Other	11 (6.5%)	18 (11.4%)	0.12	25 (17.7%)	33 (21.7%)	0.46
Medications at baseline						
Aspirin	153 (90.0%)	143 (90.5%)	0.88	105 (74.5%)	119 (78.3%)	0.44
Plavix	82 (48.2%)	70 (44.3%)	0.51	47 (33.3%)	51 (33.6%)	0.97
Ticagrelor	19 (11.2%)	28 (17.7%)	0.09	14 (9.9%)	9 (5.9%)	0.20
Prasugrel	0 (0.0%)	0 (0.0%)	1.0	0 (0.0%)	0 (0.0%)	1.0
Warfarin	6 (3.5%)	1 (0.6%)	0.12	7 (5.0%)	10 (6.6%)	0.55
NOAC	18 (10.6%)	15 (9.5%)	0.74	20 (14.2%)	26 (17.1%)	0.49
Fondaparinux	16 (9.4%)	11 (7.0%)	0.42	5 (3.6%)	7 (4.6%)	0.77
Unfractionated heparin	2 (1.2%)	7 (4.4%)	0.09	5 (3.6%)	8 (5.3%)	0.58
Low-molecular-weight heparin	2 (1.2%)	0 (0.0%)	0.50	5 (3.6%)	1 (0.7%)	0.11
Bivalirudin	1 (0.6%)	0 (0.0%)	1.0	0 (0.0%)	0 (0.0%)	1.0
GP IIa/IIIb inhibitors	0 (0.0%)	0 (0.0%)	1.0	0 (0.0%)	0 (0.0%)	1.0
Anticoagulation during procedure						
UFH use	114 (67.1%)	112 (70.9%)	0.48	44 (31.2%)	58 (38.2%)	0.21
Total dose of heparin (PCI procedure)	8,078.1±3,151.7	7,443.5±2,837.7	0.06	7,494.4±3,396.0	7,705.6±2,615.8	0.55
Final ACT	295.73±110.76	293.76±102.72	0.87	243.92±94.64	259.44±98.69	0.17
Data are expressed as mean±standard deviation (SD) or n (%). ¹ 2 patients had missing BMI values. ACT: activated clotting time; BMI: body mass index; CABG: coronary artery bypass graft; CTO: chronic total occlusion; GP: glycoprotein; NOAC: non-vitamin K antagonist oral anticoagulants; NSTEMI: non-ST-segment elevation myocardial infarction; PCI: percutaneous coronary intervention; TIA: transient ischaemic attack; UFH: unfractionated heparin; US: ultrasound						

Table 2. Procedural characteristics in patients receiving a vascular closure device (by access site, as chronic total occlusion procedures may have had two access sites).

Variables		US-guided (n=172)	Non-US-guided (n=160)	p-value
Right-sided femoral access		165 (95.9%)	152 (95.0%)	0.68
Introducer size	5 Fr	0 (0.0%)	0 (0.0%)	1.0
	6 Fr	127 (73.8%)	119 (74.4%)	0.91
	7 Fr	37 (21.5%)	37 (23.1%)	0.72
	8 Fr	7 (4.1%)	2 (1.3%)	0.17
Type of closure device	ANGIO-SEAL	141 (82.0%)	143 (89.4%)	0.06
	ProGlide	29 (16.9%)	17 (10.6%)	0.10
	Other/missing	2 (1.2%)	0 (0.0%)	0.50

Data are expressed as n (%).

95% CI: 0.74-5.07). There was, however, significant interaction (interaction p=0.034). Haematomas of more than 5 cm were approximately 3-fold more frequent in the VCD subgroup of patients randomised to no US compared to those randomised to US (4.1% vs 12.0%, OR 0.32, 95% CI: 0.11-0.81) (**Supplementary Table 3**).

Discussion

In patients who received a VCD, US- compared to non-US-guided femoral access reduced the composite of major bleeding or vascular complications in patients undergoing coronary angiography or PCI. This is likely the most important subgroup finding of the UNIVERSAL trial, as randomisation was stratified for intention to use a VCD. We also observed a reduction in major vascular complications with US in this subgroup but not a reduction in BARC 2, 3 or 5 major bleeding.

Importantly, we prespecified this subgroup and stratified the randomisation process according to planned VCD use. Before the trial, we believed that a significant interaction between US use

and VCD existed, with benefit for US use. One explanation for the finding was that in the UNIVERSAL trial, patients randomised to US-guided femoral access had fewer attempts for arterial puncture (1.16 vs 1.43; p<0.001) and fewer venipunctures (3.1% vs 11.7%; p<0.001). These data are consistent with previous meta-analyses^{8,9}. Reducing the number of arterial punctures is essential, as a VCD will only close one puncture site and will not mitigate venous bleeding. This hypothesis may be supported by our finding that large haematomas were more frequent in patients receiving VCD to close non-US-guided punctures compared to US-guided punctures. Conversely, manual compression may decrease bleeding from multiple arterial and venous punctures. US-guided femoral access allows the operator to avoid heavily calcified and diseased areas, allowing for safer and more efficacious deployment of a VCD¹⁰. However, we found that there was no difference in the rate of VCD failure between US- and non-US-guided femoral access. Previous randomised data demonstrated an increase in the efficacy of haemostasis with VCD use without a trade-off in safety, providing a strong rationale for the routine use of VCD over manual compression^{4,11}. Our data strengthens this rationale by suggesting that VCD use can be even safer with US-guided femoral access and that operators should routinely use US-guided femoral access when a VCD closure strategy is planned.

While the UNIVERSAL trial results were neutral, the updated meta-analysis of 9 randomised controlled trials including 4,410 patients comparing US-guided femoral access to non-US-guided femoral access demonstrated a significant 42% relative risk reduction in vascular complications or major bleeding, favouring US guidance⁶. Therefore, we cannot assume that the benefit of US guidance only exists for patients receiving VCD.

In the ISAR-CLOSURE trial, 3,015 patients were randomly assigned to a VCD group, and 1,509 patients were assigned to manual compression. The primary endpoint occurred in 208 (6.9%) patients assigned to a VCD and 119 (7.9%) assigned to manual compression (p for non-inferiority <0.001)⁴. The




Figure 2. Main outcomes. CI: confidence interval; US: ultrasound; VCD: vascular closure device

notably higher event rate for patients receiving a VCD in the UNIVERSAL trial is likely multifactorial: 1) ISAR-CLOSURE patients only underwent diagnostic angiography while 262/621 (42.2%) UNIVERSAL patients underwent PCI; 2) ISAR-CLOSURE patients only had 6 Fr introducers while 121/621 (19.5%) UNIVERSAL patients had introducers larger than 6 Fr; 3) ISAR-CLOSURE only recruited elective diagnostic patients while 178/621 (28.7%) of UNIVERSAL patients had non-ST-segment elevation acute coronary syndromes; and 4) UNIVERSAL included BARC 2 bleeding while no equivalent event definition was used in the ISAR-CLOSURE trial. Of note, BARC 2 bleeding accounted for most of the events in UNIVERSAL.

We did not observe a significant difference in successful cannulation of the common femoral artery, consistent with the FAUST Trial¹². One possible explanation is the effect of trainees transitioning through their learning curve, as half of the procedures were performed by interventional fellows. Another plausible explanation is that certain operators may have deliberately or inadvertently cannulated the femoral artery in a suboptimal location to avoid diseased or heavily calcified segments of the common femoral artery. Nevertheless, formal education and rigorous training are essential to developing and maintaining proper techniques.

We caution against comparisons of event rates between different closure devices in our study, as these were not randomised, and the choice may have been biased by operator and patient characteristics¹². Nevertheless, the ProGlide VCD is typically associated with a higher learning curve than the ANGIO-SEAL, and the high rate of trainee participation in the UNIVERSAL trial may have impacted the outcomes¹³.

The benefit of US in femoral access, demonstrated by the present analysis and the meta-analysis, does not obviate the superiority of transradial access over transfemoral access. The randomised controlled 2x2 factorial SURF trial of US versus no US and transfemoral versus transradial access demonstrated that transradial access was superior to transfemoral access for the primary outcome of major bleeding, major adverse cardiovascular events comprising death, stroke, myocardial infarction, urgent target lesion revascularisation, or major vascular complications at 30 days. While US increased procedural efficiency, it did not reduce the primary outcome, even in the transfemoral subgroup¹⁴.

Limitations

The present study has several limitations. First, subgroup analyses should be considered hypothesis-generating. Second, as VCD use was a post-randomisation variable, US guidance may have biased the decision to use a VCD. However, as the patient randomisation was stratified by planned VCD use, baseline characteristics, procedural characteristics, and core laboratory findings were well balanced between the US-guided and non-US-guided subgroups receiving a VCD. Furthermore, even with potential selection bias, bailout to manual compression was a safe alternative, as demonstrated in our study. Third, the majority of the VCD

used in the trial were ANGIO-SEAL devices, reducing the external validity of the results to all VCD. Fourth, the micropuncture technique was not used in the UNIVERSAL trial. However, it is plausible that using micropuncture needles mitigates the potentially deleterious effect of more inadvertent arterial punctures associated with no US use. Fifth, we did not provide a standardised definition for device failure to study investigators and caution against overinterpretation. Finally, as for the UNIVERSAL trial, the outcomes were primarily driven by BARC 2 bleeding, which is of less clinical importance than BARC 3 or 5 bleeding or vascular complications. However, a trial adequately powered for these outcomes would have required a substantial increase in the study sample size.

Conclusions

In patients receiving VCD after coronary procedures, US-guided compared to non-US-guided femoral access was associated with fewer major bleeding and vascular complications. US may be particularly beneficial when a vascular closure device is used.

Impact on daily practice

It is unknown whether ultrasound-guided femoral access reduces access site complications in the subgroup of patients receiving a vascular closure device. In patients who received a VCD, those randomised to US-guided femoral access compared to non-US-guided femoral access experienced a reduction in major bleeding or vascular complications (20/170 [11.8%] vs 37/158 [23.4%], OR 0.44, 95% CI: 0.23-0.82). In patients who did not receive a VCD, there was no difference between the US-guided and non-US-guided femoral access groups (20/141 [14.2%] vs 13/152 [8.6%], OR 1.76, 95% CI: 0.80-4.03; interaction $p=0.004$). Education and training of current and future interventional cardiologists with ultrasound for femoral access is needed.

Acknowledgements

The authors would like to acknowledge the Hamilton Health Sciences and Population Health Research Institute clinical and research personnel for their dedication to the UNIVERSAL trial.

Funding

Funding was provided by grants from the Hamilton Health Sciences Foundation and McMaster University, Division of Cardiology.

Conflict of interest statement

J. Velianou reports receiving grants or contracts, consulting fees, and payment or honoraria for lectures, presentations, speakers' bureaus, or educational events from Edwards Lifesciences; and reports receiving payment for participation on a Data Safety Monitoring Board or advisory board from Edwards Lifesciences. M. Sibbald reports receiving payment or honoraria for lectures, presentations, speakers'

bureaus, manuscript writing or educational events from Abbott and Philips. S.S. Jolly reports receiving grants or contracts from Boston Scientific; and payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Penumbra. The other authors have no conflicts of interest to declare.

References

1. Writing Committee Members; Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS Jr, Nnacheta LC, Rao SV, Sellke FW, Sharma G, Yong CM, Zwischenberger BA. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2022;79:e21-129.
2. Smilowitz NR, Kirtane AJ, Guiry M, Gray WA, Dolcimascolo P, Querijero M, Echeverry C, Kalcheva N, Flores B, Singh VP, Rabbani L, Kodali S, Collins MB, Leon MB, Moses JW, Weisz G. Practices and complications of vascular closure devices and manual compression in patients undergoing elective transfemoral coronary procedures. *Am J Cardiol*. 2012;110:177-82.
3. Robertson L, Andras A, Colgan F, Jackson R. Vascular closure devices for femoral arterial puncture site haemostasis. *Cochrane Database Syst Rev*. 2016;3:CD009541.
4. Schulz-Schupke S, Helde S, Gewalt S, Ibrahim T, Linhardt M, Haas K, Hoppe K, Böttiger C, Groha P, Bradaric C, Schmidt R, Bott-Flügel L, Ott I, Goedel J, Byrne RA, Schneider S, Burgdorf C, Morath T, Kufner S, Joner M, Cassese S, Hoppmann P, Hengstenberg C, Pache J, Fusaro M, Massberg S, Mehilli J, Schunkert H, Laugwitz KL, Kastrati A; Instrumental Sealing of Arterial Puncture Site —CLOSURE Device vs Manual Compression (ISAR-CLOSURE) Trial Investigators. Comparison of vascular closure devices vs manual compression after femoral artery puncture: the ISAR-CLOSURE randomized clinical trial. *JAMA*. 2014;312:1981-7.
5. Dahal K, Rijal J, Shahukhal R, Sharma S, Watti H, Azrin M, Katikaneni P, Jimenez E, Tandon N, Modi K, Lee J. Comparison of manual compression and vascular hemostasis devices after coronary angiography or percutaneous coronary intervention through femoral artery access: A meta-analysis of randomized controlled trials. *Cardiovasc Revasc Med*. 2018;19:151-62.
6. Jolly SS, AlRashidi S, d'Entremont MA, Alansari O, Brochu B, Heenan L, Skuriat E, Tyrwhitt J, Raco M, Tsang M, Valettas N, Velianou JL, Sheth T, Sibbald M, Mehta SR, Pinilla-Echeverri N, Schwalm JD, Natarajan MK, Kelly A, Akl E, Tawadros S, Camargo M, Faidi W, Bauer J, Moxham R, Nkurunziza J, Dutra G, Winter J. Routine Ultrasonography Guidance for Femoral Vascular Access for Cardiac Procedures: The UNIVERSAL Randomized Clinical Trial. *JAMA Cardiol*. 2022;7:1110-8.
7. Alrashidi S, d'Entremont M-A, Alansari O, Winter J, Brochu B, Heenan L, Skuriat E, Tyrwhitt J, Raco M, Tsang MB, Valettas N, Velianou J, Sheth T, Sibbald M, Mehta SR, Pinilla-Echeverri N, Schwalm JD, Natarajan MK, Kelly A, Akl E, Tawadros S, Camargo M, Faidi W, Dutra G, Jolly SS. Design and Rationale of Routine Ultrasound Guidance for Vascular Access for Cardiac Procedures: A Randomized Trial (UNIVERSAL). *CJC Open*. 2022;4:1074-80.
8. Sorrentino S, Nguyen P, Salerno N, Polimeni A, Sabatino J, Makris A, Hennessy A, Giustino G, Spaccarotella C, Mongiardo A, De Rosa S, Juergens C, Indolfi C. Standard Versus Ultrasound-Guided Cannulation of the Femoral Artery in Patients Undergoing Invasive Procedures: A Meta-Analysis of Randomized Controlled Trials. *J Clin Med*. 2020;9:677.
9. Rashid MK, Sahami N, Singh, Winter J, Sheth T, Jolly SS. Ultrasound Guidance in Femoral Artery Catheterization: A Systematic Review and a Meta-Analysis of Randomized Controlled Trials. *J Invasive Cardiol*. 2019;31:E192-8.
10. Bangalore S, Barsness GW, Dangas GD, Kern MJ, Rao SV, Shore-Lesserson L, Tamis-Holland JE. Evidence-Based Practices in the Cardiac Catheterization Laboratory: A Scientific Statement From the American Heart Association. *Circulation*. 2021;144:e107-19.
11. Holm NR, Sindberg B, Schou M, Maeng M, Kaltoft A, Böttcher M, Krusell LR, Hjort J, Thuesen L, Terkelsen CJ, Christiansen EH, Botker HE, Kristensen SD, Lassen JF; CLOSE-UP study group. Randomised comparison of manual compression and FemoSeal vascular closure device for closure after femoral artery access coronary angiography: the CLOSURE dEVICES Used in everyday Practice (CLOSE-UP) study. *EuroIntervention*. 2014;10:183-90.
12. Seto AH, Abu-Fadel MS, Sparling JM, Zacharias SJ, Daly TS, Harrison AT, Suh WM, Vera JA, Aston CE, Winters RJ, Patel PM, Hennebry TA, Kern MJ. Real-time ultrasound guidance facilitates femoral arterial access and reduces vascular complications: FAUST (Femoral Arterial Access With Ultrasound Trial). *JACC Cardiovasc Interv*. 2010;3:751-8.
13. Bangalore S, Bhatt DL. Femoral arterial access and closure. *Circulation*. 2011;124:e147-56.
14. Nguyen P, Makris A, Hennessy A, Jayanti S, Wang A, Park K, Chen V, Nguyen T, Lo S, Xuan W, Leung M, Juergens C. Standard versus ultrasound-guided radial and femoral access in coronary angiography and intervention (SURF): a randomised controlled trial. *EuroIntervention*. 2019;15:e522-30.

Supplementary data

Supplementary Table 1. Vascular closure device failure (by access site).

Supplementary Table 2. Core laboratory findings in patients receiving a vascular closure device (by access site).

Supplementary Table 3. Vascular complications, large haematoma, and BARC 2 bleeding in US-guided vs non-US-guided femoral access by VCD use.

The supplementary data are published online at:

<https://eurointervention.pronline.com/>

doi/10.4244/EIJ-D-22-01130

